Postmenopausal women may achieve greater weight loss by combining hormone therapy with tirzepatide, a GLP-1-based obesity medication, according to a Mayo Clinic study. The research showed that women using hormone therapy lost an average of 19.2% of their body weight over 12 months, compared to 14.0% for those taking tirzepatide alone, representing a 35% increase in weight loss. The study, published in February in The Lancet Obstetrics, Gynaecology, & Women’s Health, suggests that hormone therapy could be a viable strategy for addressing weight gain related to menopause, a period marked by hormonal changes that elevate health risks. While the findings indicate a correlation between hormone therapy and enhanced weight loss, researchers caution that the observational nature of the study does not establish a direct cause-and-effect relationship.
Why It Matters
Weight gain after menopause can increase the risk of obesity, cardiovascular disease, and Type 2 diabetes. Hormone therapy is commonly prescribed to alleviate menopausal symptoms, and the integration of tirzepatide may offer a dual approach to managing both symptoms and weight. Previous studies have shown that hormonal changes significantly impact metabolism and appetite regulation in women. Ongoing research is necessary to determine the safety and efficacy of this combination treatment, as well as its effects on broader cardiometabolic health outcomes for postmenopausal women.
Want More Context? 🔎
